Covid-19: Global Vaccine Inequity

Baroness Greengross Excerpts

Wednesday 27th April 2022 Lords Chamber

[Lord Ahmad of Wimbledon (Con)]

My Lords, this is a serious matter that requires a serious response. The fact is that the Government have got their priorities right. It was entirely appropriate, when it came to vaccine delivery and vaccinations, that we ensured that our own population was prioritised, and we delivered on that. We have led the world on manufacturing. The noble Lord knows that it was our association with India—a country mentioned in the previous Question—that led to the upscaling of manufacturing when it came to the vaccines, when the world needed it most. Yes, logistics is an issue: the noble Lord and I have talked about this. That is why we are currently working in Sierra Leone, Ethiopia, Uganda and Nigeria on that very issue of logistics and structures to ensure—whether it is for this variant or the next or for any vaccine—that the structures set up, particularly in the global south, are robust enough to deal with this continuing pandemic.

[Baroness Greengross (CB)]

My Lords, is stockpiling not one of the issues we should address? It seems to me very immoral that wealthier nations stockpile. Amnesty has pointed this out. If we had a proper human rights framework, it could not happen. Should we not do something to ensure that many of the wealthier nations do not stockpile while others are finding it very difficult to get adequate amounts of vaccines? We need to find solutions as a matter of urgency.

[Lord Ahmad of Wimbledon (Con)]

My Lords, the noble Baroness refers to the earlier stages of the vaccines. As vaccines were being developed, undoubtedly those countries that were first in production and manufacturing held vaccines in reserve, but the whole essence of the accelerator within the COVAX scheme was to ensure that the most vulnerable were provided with supplies of vaccines. As I said in response to the question from the noble Lord, Lord Collins, the issue within countries has been one of logistics. There have, sadly, been examples where the supply has reached a port of a given country, but where the challenge has been the duration of the shelf life of the vaccine and the logistics within country. That is where we are currently focused, particularly when it comes to second doses and booster vaccines in the global south.